A specific chemical alteration to a single protein may be the mechanism that sustains destructive brain inflammation in Alzheimer’s disease, according to researchers at Scripps Research in La Jolla. The finding identifies a precise molecular target for potential drug development.
The protein STING normally functions as an immune sentinel, activating inflammatory signals in response to threats such as viruses. In Alzheimer’s disease, however, the protein undergoes a chemical change at a specific location — the amino acid cysteine 148. This modification locks STING into a persistently hyperactive state, causing it to continuously release inflammatory signals even in the absence of any real threat.
This chronic inflammation damages the synaptic connections between neurons. These connections are precisely what Alzheimer’s patients lose as their cognitive abilities decline.
The protein clumps that characterize Alzheimer’s — amyloid-beta and alpha-synuclein — can trigger this modification, initiating a cycle where inflammation fuels further inflammation. Neurologist Stuart Lipton led the research team. In experiments with mice, blocking this specific modification significantly reduced neuroinflammation.
Critically, the synaptic connections remained intact. The work represents a shift in the field’s approach.
For years, drug development efforts concentrated on clearing amyloid plaques from the brain. Those clinical trials largely failed to improve patient outcomes. This research points to inflammation as a driving force in the disease, rather than merely a secondary effect.
The precision of the target is notable. The modification occurs at a single point on a large protein.
Blocking that one change suppresses the harmful overactivation while leaving the rest of STING’s normal function intact. This means the immune system could still fight infections — a significant advantage over broad anti-inflammatory drugs, which suppress all immune activity and create risks. The researchers are now working on small molecules designed to block this specific modification. This is not yet a treatment, but it provides a roadmap for designing drugs that target only the harmful signal.
Factors that increase nitric oxide levels in the brain — including aging, air pollution, and wildfire smoke — can drive this process. This suggests environmental exposures may be contributing to the molecular switch.
While a link between pollution and dementia has been observed previously, this research offers a clear mechanism connecting smoke to chemical change to immune overdrive. The work remains preliminary. Results from mice do not always translate to humans.
However, the logic of a precise switch, a precise blocker, and a preserved immune system represents a combination that has proven elusive in Alzheimer’s research. Lipton’s team has not announced a timeline for human trials.
They are in the early stages of developing compounds. The National Institutes of Health funded the work, and Scripps Research holds patents on the technology. Alzheimer’s disease affects more than six million Americans.
No drug currently stops or reverses the disease. Approved treatments offer only modest symptom relief.
This finding does not promise a cure, but it identifies a specific, druggable point on a single protein — a target that has been absent from the field for years.
